Download PDF
Hamostaseologie 2009; 29(02): 137-142
DOI: 10.1055/s-0037-1617026
Original Article
Schattauer GmbH

Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare

Erworbenes von-Willebrand-Syndrom als unerwünschte Arzneimittelwirkung der Therapie mit Valproinsäure bei Kindern ist selten
W. Eberl
1   Department of Paediatrics and Coagulation Laboratory, Klinikum Braunschweig gGmbH
,
U. Budde
2   Coagulation Laboratory, AescuLabor Hamburg
,
K. Bentele
3   Department of General Paediatrics, University Medical Center Hamburg-Eppendorf
,
H.-J. Christen
4   Children’s Hospital ,,auf der Bult“, Hannover
,
R. Knapp
1   Department of Paediatrics and Coagulation Laboratory, Klinikum Braunschweig gGmbH
,
A. Mey
1   Department of Paediatrics and Coagulation Laboratory, Klinikum Braunschweig gGmbH
,
R. Schneppenheim
4   Children’s Hospital ,,auf der Bult“, Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

To determine the frequency and clinical relevance of acquired von Willebrand syndrome (aVWS) due to antiepileptic therapy by valproic acid, we investigated 50 consecutive children in three neuropediatric institutions. Coagulation factors were determined in local laboratories before and three times after starting therapy with valproic acid. Parameters of von Willebrand factor (VWF) were additionally investigated in a reference laboratory including multimeric analysis. Significant changes in the coagulation system were found concerning fibrinogen (decreased from 287 ± 70 mg/dl to 222 ± 67 mg/dl; p < 0.001) and platelet count. Changes of VWF para -meters were also found but no patient developed laboratory defined aVWS. We conclude that the bleeding tendency observed in some children undergoing antiepileptic therapy with valproic acid is not due to aVWS.

Zusammenfassung

Um die Häufigkeit und die Relevanz eines durch eine antiepileptische Valproat-Therapie erworbenen von-Willebrand-Syndroms (VWS) bei Kindern zu erfassen, untersuchten wir 50 konsekutive Fälle in drei neuropädiatrischen Institutionen. Hämostaseparameter wurden vorher und dreimal im Laufe der Therapie erhoben. Von-Willebrand-Faktor(VWF)-Para -meter einschließlich Multimeranalyse, wurden zusätzlich in einem Referenzlabor bestimmt. Die Behandlung der Kinder mit Valproinsäure führte zu häufigen Veränderungen der Hämostase wie Hypofibrinogenämie (Abfall von 287 ± 70 mg/dl auf 222 ± 67 mg/dl; p < 0,001) und Thrombozytopenie. Veränderungen der VWF-Parameter waren jedoch marginal und rechtfertigten bei keinem Patienten die Diagnose eines erworbenen VWS. Die bei einigen Patienten beobachtete Blutungsneigung unter Valproinsäure ist daher nicht auf ein erworbenes VWS zurückzuführen.

Keywords

Acquired von Willebrand syndrome - valproic acid

Schlüsselwörter

Erworbenes von-Willebrand-Syndrom - Valproat
 

  • References

  • 1 Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-65.
    CrossrefPubMedGoogle Scholar
  • 2 Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002; 43 (Suppl. 03) 53-59.
    CrossrefPubMedGoogle Scholar
  • 3 Banerjea M, Diener W, Kutschke G. et al. Valproat und Hämostase. In: Gross-Selbeck G. (Hrsg). Aktuelle Neuropädiatrie 1995. Ciba-Geigy: 1996
    Google Scholar
  • 4 Banerjea MC, Diener W, Kutschke G. et al. Pro- and anticoagulatory factors under sodium valproate-therapy in children. Neuropediatrics 2002; 33: 215-220.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Barr RD, Copeland SA, Stockwell ML. et al. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57: 681-684.
    CrossrefPubMedGoogle Scholar
  • 6 Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462-466.
    CrossrefPubMedGoogle Scholar
  • 7 Dale BM, Purdie GH, Rischbieth RH. Fibrinogen depletion with sodium valproate. Lancet 1978; 1: 1316-1317.
    PubMedGoogle Scholar
  • 8 Delgano MR, Riela AR, Mills J. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994; 9: 311-314.
    CrossrefPubMedGoogle Scholar
  • 9 Gidal B, Spencer N, Maly M. et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994; 44: 1418-1422.
    CrossrefPubMedGoogle Scholar
  • 10 Gill JC, Endres-Brooks J, Bauer PJ. et al. The effect of ABO blood group on the diagnosis of von Wille-brand disease. Blood 1987; 69: 1691-1695.
    PubMedGoogle Scholar
  • 11 Hauser E, Seidl R, Freilinger M. et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996; 18: 105-109.
    CrossrefPubMedGoogle Scholar
  • 12 Jacobi G, Thorbeck R, Ritz A. et al. Fatal hepatotoxicity in child on phenobarbitone and sodium valproate. Lancet 1980; 1 8170 712-713.
    PubMedGoogle Scholar
  • 13 König SA, Eiger CE, Vasella F. Empfehlungen zur Blutuntersuchung und der klinischen Über -wachung zur Früherkennung des Valproat-assoziierten Leberversagens. Mschr Kinderheilk 1999; 147: 718-723.
    PubMedGoogle Scholar
  • 14 Kreuz W, Linde R, Funk M. et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1992; 33: 178-184.
    CrossrefPubMedGoogle Scholar
  • 15 Kreuz W, Linde R, Funk M. et al. Induction of von Willebrand disease type I by valproic acid. Lancet 1990; 335: 1350-1351.
    PubMedGoogle Scholar
  • 16 Kreuz W, Mentzer D, Becker S. et al. Haemate P in children with von Willebrand‘s disease. Haemostasis 1994; 24: 304-310.
    PubMedGoogle Scholar
  • 17 Loiseau P. Sodium valproate, platelet dysfunction, and bleeding. Epilepsia 1981; 22: 141-146.
    CrossrefPubMedGoogle Scholar
  • 18 Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 1979; 5: 389-390.
    CrossrefPubMedGoogle Scholar
  • 19 Nitu-Whalley IC, Lee CA, Griffioen A. et al. Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-264.
    CrossrefPubMedGoogle Scholar
  • 20 Ojemann LM, Wilensky AJ. Fibrinogen and valproic acid. Epilepsia 1981; 22: 242-243.
    PubMedGoogle Scholar
  • 21 Pohlmann-Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003; 108: 142-145.
    CrossrefPubMedGoogle Scholar
  • 22 Sadler JE. A revised classification of von Willebrand disease. For the subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-525.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Sandler RM, Bevan PC, Roberts GE. et al. Interaction between sodium valproate and platelets: a further study. Br Med J 1979; 2: 1476.
    PubMedGoogle Scholar
  • 24 Voss H, Petrich C, Schulz HU. Hemorrhagic diathesis and platelet dysfunction in children under treatment with sodium valproate. Epilepsia 1978; 19: 113-114.
    PubMedGoogle Scholar
  • 25 Serdaroglu G, Tutuncuoglu S, Kavakli K, Tekgul H. Coagulation abnormalities and acquired von Willebrand‘s disease type 1 in children receiving valproic acid. J Child Neurol. 2002; 17: 41-43.
    CrossrefPubMedGoogle Scholar
  • 26 Sussman NM, McLain Jr LW. A direct hepatotoxic effect of valproic acid. JAMA 1979; 242: 1173-1174.
    CrossrefPubMedGoogle Scholar
  • 27 Sutor AH. Jesdinsky-Buscher. Gerinnungsveränderungen durch Dipropylessigsäure. Med Welt 1974; 25: 447-449.
    PubMedGoogle Scholar
  • 28 Zeitler P, Mingers AM. Gerinnungsveränderungen unter Valproattherapie. Mschr Kinderheilk 1995; 143: 949.
    PubMedGoogle Scholar